HSBC Maintains Reduce on Biogen, Raises Price Target to $175
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.
HSBC analyst Rajesh Kumar maintains Biogen (NASDAQ:BIIB) with a Reduce and raises the price target from $165 to $175.